vorinostat has been researched along with Osteolysis in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Osteolysis: Dissolution of bone that particularly involves the removal or loss of calcium.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat-treated and control mice without tumors were also examined." | 5.36 | The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. ( Akech, J; Bedard, K; Dhillon, RJ; Hussain, S; Li, X; Lian, JB; McGee-Lawrence, ME; Pratap, J; Stein, GS; Stein, JL; Szabo, G; van Wijnen, AJ; Westendorf, JJ; Wixted, JJ, 2010) |
| "Vorinostat-treated and control mice without tumors were also examined." | 1.36 | The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. ( Akech, J; Bedard, K; Dhillon, RJ; Hussain, S; Li, X; Lian, JB; McGee-Lawrence, ME; Pratap, J; Stein, GS; Stein, JL; Szabo, G; van Wijnen, AJ; Westendorf, JJ; Wixted, JJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pratap, J | 1 |
| Akech, J | 1 |
| Wixted, JJ | 1 |
| Szabo, G | 1 |
| Hussain, S | 1 |
| McGee-Lawrence, ME | 1 |
| Li, X | 1 |
| Bedard, K | 1 |
| Dhillon, RJ | 1 |
| van Wijnen, AJ | 1 |
| Stein, JL | 1 |
| Stein, GS | 1 |
| Westendorf, JJ | 1 |
| Lian, JB | 1 |
1 other study available for vorinostat and Osteolysis
| Article | Year |
|---|---|
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss.
Topics: Animals; Bone and Bones; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Extr | 2010 |